Baidu
map

互联网+时代背景下,中国高血压管理如何实现规范化、智慧化?

2019-12-15 杨亚平 健康界

高血压已成为我国重大的公共卫生问题。据最新心血管报告显示,我国高血压的知晓率、治疗率及控制率分别为50%、45%和16%左右,而我国的高血压患病人数从1958年不足3000万人增长到了3亿人,控制达标的高血压患者不到五分之一。“健康中国2030”规划纲要提出,2030年力争将高血压的知晓率、治疗率及控制率分别提高至70%、99%和50%。那么,在当今互联网+的时代背景下,互联网能否有效提高“三率”

高血压已成为我国重大的公共卫生问题。据最新心血管报告显示,我国高血压的知晓率、治疗率及控制率分别为50%、45%和16%左右,而我国的高血压患病人数从1958年不足3000万人增长到了3亿人,控制达标的高血压患者不到五分之一。“健康中国2030”规划纲要提出,2030年力争将高血压的知晓率、治疗率及控制率分别提高至70%、99%和50%。

那么,在当今互联网+的时代背景下,互联网能否有效提高“三率”,推动中国高血压规范化、智慧化管理,实现高血压拐点早日到来?

近日,以“开拓、共融、共铸健康中国梦”为主题的2019华夏互联网+高血压峰会在北京召开。该峰会秉承跨界融合的理念,汇集各领域专家学者,从医学人文、经济,医疗信息化、高血压慢病管理、互联网+医疗时代的慢病管理等热点话题,借助互联网+高血压峰会这一平台,实现多维度交流。

中国医疗保健国际交流促进会一直将“互联网、智慧医疗、跨界交流和开创融合”作为会议宗旨,通过促进学科和行业间的交流和对话,开展不同层次的创新及合作。

“四年前,我们还在讨论什么是互联网?要怎么参与进来?而四年后的今天,随着科技的发展,互联网已经完全渗透到我们的生活中,医疗领域更是把互联网视为一个不可缺少的有效工具,并运用到各个层面。”大会主席、中国医疗保健国际交流促进会高血压分会主任委员、中国医师协会高血压专业委员会名誉主任委员、北京大学人民医院孙宁玲教授指出,当前,人工智能(AI)将医学发展迅速推到了一个崭新的高度。互联网带动了医学的发展,此次“互联网+高血压峰会”将积极应对这一的巨大转变,并以全新地姿态与时代共同进步。

2011年世界卫生组织(WHO)设立目标,呼吁将四类疾病,即心血管疾病、肿瘤、慢性呼吸道疾病、糖尿病的发病率控制下来,不让可持续发展成为一句空话。因此,健康被视为社会、经济、环境发展的前提。

世界高血压联盟前任主席、中国高血压联盟终身名誉主席刘力生教授表示,“我国是人口大国,特别是在心血管方面。高血压是心血管疾病的首要危险因素,我国有非常庞大的高血压患病人群,防控形势严峻。我国慢性病防治中长期规划要求,到2020年,将我国1亿高血压患者的血压水平控制在140/90 mmHg以下。尽管在高血压领域专家的不懈努力下,制定了基层和患者教育等众多指南,并逐步落实到基层。但打通落地的‘最后一公里’,我们依然面临挑战。”

刘力生教授表示,高血压的防治决不仅限于卫生领域,各个学科需要共同努力。互联网+和AI的快速发展为我国高血压的防控提供了新的手段,高血压防治未来的道路会更宽、机会更多。

中国医学科学院副院长、北京协和医学院副校长李青教授希望从事信息技术、互联网+的专业人士能够与医药卫生领域的科技工作者一起碰撞出思想的火花,用颠覆性的思维和方法实现数据整合,共同推动高血压领域精准医学的发展。

国家卫生健康委医政医管局医疗资源处胡瑞荣副处长表示,此次会议主题非常契合我国现有政策和方针。“本次峰会既契合了互联网+医疗健康的工作,又体现了分级诊疗制度的建设,意义重要而深远。”胡瑞荣副处长指出,当前互联网诊疗发展迅猛,据不完全统计,去年全国范围内互联网诊疗行为共发生了4000多万亿次,未来还会更多。“这一技术手段,让我们打破了时间和空间的界限,更好地管理患者,另外,互联网+的技术手段进一步丰富了分级诊疗工作的落实。”

我国是高血压大国,高血压的防治实际上已经超越了医学的范畴。中国医疗保健国际交流促进会吕兆丰副会长指出,在5G时代来临之际,将高血压的管理与信息技术相结合,带来了全新的局面,也意味着“健康中国2030”发展纲要提出之后,医学的发展出现了新的闭环,以往包括临床医学、预防医学、康复医学,以及正在形成的健康医学。“高血压实际跨越了这四大医学方面,而互联网和AI技术的加入,必将为我国高血压的管理带来新的飞跃。”

“人文、经济大咖谈”是本次大会的亮点之一,来自各领域的专家分别以TED演讲的方式,为大家分享了大国经济与健康医疗、医生的尊严、走好人生路、科学技术与医学、健康在自己手中、移动时代知识的真正价值等内容。用最前沿的观点,阐述了人工智能改变医疗形态的趋势下,医学发展与社会、人文、经济产生的千丝万缕的联系。全面诠释了社会大背景下,医务人员如何适应政经潮流,掌握人生方向,以及展现医疗本质和实现价值,让人耳目一新。

会议期间,专家们还就医疗信息化在疾病管理中的作用、高血压的防治策略、不同高血压临床管理路径、血脂管理模式、最新高血压研究进展、糖尿病与心血管疾病、高血压治疗如何实现达标、互联网+医疗时代的慢病管理等内容进行了学习交流。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1946153, encodeId=3484194615313, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 29 14:18:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691402, encodeId=849016914024c, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Mar 17 03:18:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274296, encodeId=c95a12e4296f5, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344335, encodeId=8b46134433571, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438091, encodeId=96891438091a4, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377014, encodeId=2eab3e70142f, content=学习了,谢谢分成, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 16 07:07:50 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377013, encodeId=5c4e3e7013d1, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Dec 16 07:06:06 CST 2019, time=2019-12-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1946153, encodeId=3484194615313, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 29 14:18:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691402, encodeId=849016914024c, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Mar 17 03:18:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274296, encodeId=c95a12e4296f5, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344335, encodeId=8b46134433571, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438091, encodeId=96891438091a4, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377014, encodeId=2eab3e70142f, content=学习了,谢谢分成, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 16 07:07:50 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377013, encodeId=5c4e3e7013d1, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Dec 16 07:06:06 CST 2019, time=2019-12-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1946153, encodeId=3484194615313, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 29 14:18:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691402, encodeId=849016914024c, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Mar 17 03:18:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274296, encodeId=c95a12e4296f5, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344335, encodeId=8b46134433571, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438091, encodeId=96891438091a4, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377014, encodeId=2eab3e70142f, content=学习了,谢谢分成, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 16 07:07:50 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377013, encodeId=5c4e3e7013d1, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Dec 16 07:06:06 CST 2019, time=2019-12-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1946153, encodeId=3484194615313, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 29 14:18:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691402, encodeId=849016914024c, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Mar 17 03:18:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274296, encodeId=c95a12e4296f5, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344335, encodeId=8b46134433571, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438091, encodeId=96891438091a4, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377014, encodeId=2eab3e70142f, content=学习了,谢谢分成, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 16 07:07:50 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377013, encodeId=5c4e3e7013d1, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Dec 16 07:06:06 CST 2019, time=2019-12-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1946153, encodeId=3484194615313, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 29 14:18:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691402, encodeId=849016914024c, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Mar 17 03:18:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274296, encodeId=c95a12e4296f5, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344335, encodeId=8b46134433571, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438091, encodeId=96891438091a4, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377014, encodeId=2eab3e70142f, content=学习了,谢谢分成, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 16 07:07:50 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377013, encodeId=5c4e3e7013d1, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Dec 16 07:06:06 CST 2019, time=2019-12-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1946153, encodeId=3484194615313, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 29 14:18:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691402, encodeId=849016914024c, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Mar 17 03:18:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274296, encodeId=c95a12e4296f5, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344335, encodeId=8b46134433571, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438091, encodeId=96891438091a4, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377014, encodeId=2eab3e70142f, content=学习了,谢谢分成, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 16 07:07:50 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377013, encodeId=5c4e3e7013d1, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Dec 16 07:06:06 CST 2019, time=2019-12-16, status=1, ipAttribution=)]
    2019-12-16 1ddf0692m34(暂无匿称)

    学习了,谢谢分成

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1946153, encodeId=3484194615313, content=<a href='/topic/show?id=f6fb102e02e4' target=_blank style='color:#2F92EE;'>#高血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102702, encryptionId=f6fb102e02e4, topicName=高血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Dec 29 14:18:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691402, encodeId=849016914024c, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Tue Mar 17 03:18:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274296, encodeId=c95a12e4296f5, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344335, encodeId=8b46134433571, content=<a href='/topic/show?id=683a88964b0' target=_blank style='color:#2F92EE;'>#血压管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88964, encryptionId=683a88964b0, topicName=血压管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1438091, encodeId=96891438091a4, content=<a href='/topic/show?id=e08c2412394' target=_blank style='color:#2F92EE;'>#互联网+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24123, encryptionId=e08c2412394, topicName=互联网+)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Dec 17 13:18:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377014, encodeId=2eab3e70142f, content=学习了,谢谢分成, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Mon Dec 16 07:07:50 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377013, encodeId=5c4e3e7013d1, content=学习了很有用不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Mon Dec 16 07:06:06 CST 2019, time=2019-12-16, status=1, ipAttribution=)]
    2019-12-16 飛歌

    学习了很有用不錯

    0

相关资讯

以顽固性头痛、高血压为首发表现的椎动脉动脉瘤1例

男,42岁,因反复头痛3年、加剧4 d入住我院心内科。入院前3年,多于疲劳或精神紧张出现头痛,呈阵发性搏动性胀痛,程度轻中度,每次持续数分钟至数小时,休息后可好转。曾就诊于当地医院,测血压偏高,此后多次测血压至少3次非同日血压大于140/90 mmHg,最高达180/120 mmHg,诊为“高血压病3级”,予降压治疗(药名不详),症状缓解,此后未行系统诊治,服药规律,测血压均偏高,头痛症状仍时有发

有高血压者睡觉别超8小时!中国高血压调查全新分析:超8小时增中风危险

关于睡眠时间与中风之间的关系,目前的研究结果并不一致。12月9月,南昌大学第二附属医院程晓曙教授团队联合阜外医院高润霖院士、王增武教授发表的中国高血压调查研究最新分析结果提示,在高血压患者与血压正常人群中,睡眠时间与中风之间的关系不尽相同。研究者发现,平均睡眠时间为8小时时,高血压患者的中风危险最低。而当睡眠时间超过8小时时,中风风险增加60%。然而,在血压正常的中老年人群中,随着睡眠时间延长,中

J Diabetes:老公吸烟,老婆倒霉,中国千万对夫妇调查,可致糖尿病和高血压

近期一项由国家卫生健康委科研所、国家心血管病中心阜外医院等多家单位在1000万余对夫妻中进行的研究显示,丈夫吸烟,妻子易患糖尿病。丈夫烟瘾越重,妻子风险越高。

中国200万对夫妻研究:有高血压的人不易怀孕

高血压是常见病了,但是这个病并不简单,和糖尿病等很多疾病都有千丝万缕的关系,而近日一项中美学者在我国200万对夫妻中进行的研究则表明:上天不赐于宝宝,或许就是由于夫妻双方或其中一方有高血压的缘故。研究发现,与夫妻双方血压都正常相比,夫妻双方都有高血压会降低27%的怀孕可能性。研究显示,在试验进行的1年内,妻子有高血压的怀孕率为33.9%,有高血压前期怀孕率为41.6%,正常血压者则为42.2%。对

“ADVANCE-降压降糖风险管理”项目阶段性研讨会在沪成功举办

2019年9月17日,来自全国心血管和内分泌领域的专家齐聚上海,以新型的会议模式,共同探讨ESH/ESC热点话题,培哚普利吲达帕胺片在高盐摄入和高血压合并糖尿病两类人群的治疗优势,及磺脲类药物降糖方案的心脏安全及肾脏获益。

中国高血压调查全新分析:温带地区血压随气温呈“U”型变化,亚热带收缩压受低温影响很大

有人说,北方的冷是物理的,南方的冷是魔性的,一个攻击肉体,一个攻击骨髓。不论如何,居住在不同的气候带,温度的变化总是会引起身体的不同反应。近日,中国高血压调查最新分析显示,不同气候带的环境温度对人体血压的影响是不同的,而且最宜人温度也差距很大。研究显示,对于居住在温带季风性或大陆性气候带的人群,环境温度和血压呈“U”型曲线,也就是说,过高过低的温度均会增加高血压风险,而20°C~25°C最宜人。图

Baidu
map
Baidu
map
Baidu
map